2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Urinary Bladder Neoplasms
2
Postoperative Complications
2
Neoplasms
2
Malnutrition
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder, Neurogenic
1
Urinary Bladder Diseases
1
Small Cell Lung Carcinoma
1
Frailty
1
Esophagitis
1
Endometriosis
1
Cystitis, Interstitial
1
Cystitis, Hemorrhagic
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Etoposide
156
Carboplatin
146
Cisplatin
106
Topotecan
76
durvalumab
52
atezolizumab
51
Irinotecan
45
pembrolizumab
39
Paclitaxel
34
Nivolumab
33
Radiotherapy
31
PM 01183
25
Drug Therapy
24
anlotinib
23
Gemcitabine
21
apatinib
19
Ipilimumab
18
Docetaxel
17
Temozolomide
16
Platinum
16
Radiosurgery
15
Pemetrexed
14
toripalimab
13
tislelizumab
13
olaparib
13
Magnetic Resonance Spectroscopy
13
Bevacizumab
13
rovalpituzumab tesirine
11
amrubicin
11
Specimen Handling
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Immunonutrition Diet
×
Clear all
NCT06840704
2026-04-02
Relief
Hunan Cancer Hospital
Phase 3
Recruiting
121 enrolled